Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
Orange, California, Forente stater, 92868-3298
- University of California, Irvine
-
Orange, California, Forente stater, 92868
- Chao Family Comprehensive Cancer Center UC Irvine Medical Center
-
Pleasant Hill, California, Forente stater, 94523
- Bay Area Cancer Research Group, LLC
-
Salinas, California, Forente stater, 93901
- Pacific Cancer Care
-
San Francisco, California, Forente stater, 94110
- San Francisco General Hospital
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University Of Colorado Hospital
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Clinical Trials Office (CTO)
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33919
- Florida Cancer Specialists
-
-
Maryland
-
Bethesda, Maryland, Forente stater, 20892
- National Institutes of Health National Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Forente stater, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Forente stater, 02115
- Brigham & Women's Hospital
-
Boston, Massachusetts, Forente stater, 02210
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Forente stater, 02210
- Dana-Farber Cancer lnstitute
-
-
Missouri
-
Springfield, Missouri, Forente stater, 65804
- St. John's Hospital,
-
-
New York
-
New York, New York, Forente stater, 10022
- Memorial Sloan-Kettering Cancer Center
-
Stony Brook, New York, Forente stater, 11794-9446
- Stony Brook University Medical Center - Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Investigational Drug Service, Pharmacy Department, UNC Hospitals
-
Chapel Hill, North Carolina, Forente stater, 27599-7600
- UNC Hospitals, The University of North Carolina at Chapel Hill
-
Chapel Hill, North Carolina, Forente stater, 27599-2008
- Division of Hemotology/Oncology
-
Durham, North Carolina, Forente stater, 27710
- Morris Cancer Center
-
-
North Dakota
-
Bismarck, North Dakota, Forente stater, 58501
- Legacy Pharma Research
-
Bismarck, North Dakota, Forente stater, 58501
- Mid Dakota Clinic, P.C
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37404
- Chattanooga Oncology & Hematology Associates, P.C.
-
Nashville, Tennessee, Forente stater, 37203 (Administration)
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Forente stater, 37203(Pharmacy)
- Sarah Cannon Research Institute
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23230
- Virginia Cancer Institute
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Seattle Cancer Care Alliance
-
Seattle, Washington, Forente stater, 98195
- University of Washington Medical Center
-
-
-
-
-
New Territories, Hong Kong
- Department of Clinical Oncology, Tuen Mun Hospital
-
Shatin, NT, Hong Kong
- Prince of Wales Hospital
-
-
NEW Territories
-
Tuen Mun, NEW Territories, Hong Kong
- Department of Clinical Oncology, Tuen Mun Hospital
-
Tuen Mun, NEW Territories, Hong Kong
- Department of Clinical Oncology, Tuen Mun Hospital
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi cancer center central hospital Thoracic Oncology
-
-
Tokyo
-
Koto-Ku, Tokyo, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
-
-
-
-
Seoul, Korea, Republikken, 110-744
- Seoul National University Hospital
-
Seoul, Korea, Republikken, 120-752
- Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center
-
Seoul, Korea, Republikken, 135-710
- SamsungMedicalCenter, Sungkyunkwan Univ School of Medicine
-
-
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Advanced adenocarcinoma of lung, measurable disease
- Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR
- patients with known EGFR activating mutation regardless of smoking status
- ECOG(Eastern Cooperative Oncology Group) 0-1.
Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy
Exclusion Criteria:
- Active brain metastases
- Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.
- known EGFR wild type NSCLC
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort A
Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
|
Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
|
|
Eksperimentell: Cohort B
Dacomitinib in patients with HER2 mutated or amplified NSCLC
|
Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS) at Month 4: Cohort A
Tidsramme: Baseline up to Month 4
|
PFS at Month 4 was defined as percentage of participants who were alive and event free (event defined as progressive disease [PD] or death due to any cause, whichever occurs first) at 4 months after the first dose of study treatment.
Documentation of progression was based on Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0) criteria.
PD = greater than or equal to (>=) 20 percent (%) increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the start of treatment, or the appearance of 1 or more new lesions, or unequivocal progression in non-target lesions.
|
Baseline up to Month 4
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS) at Month 4: Cohort B
Tidsramme: Baseline up to Month 4
|
PFS at Month 4 was defined as percentage of patients who were alive and event free (event defined as PD or death due to any cause, whichever occurs first) at 4 months after the first dose of study treatment.
Documentation of progression was based on RECIST v1.0 criteria.
PD: >=20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the start of treatment, or the appearance of 1 or more new lesions, or unequivocal progression in non-target lesions.
|
Baseline up to Month 4
|
|
Progression-Free Survival (PFS)
Tidsramme: Baseline until progression or initiation of new anti-cancer therapy or death, assessed at baseline, at the end of Cycle 1, Cycle 2, and then every other cycle.
|
PFS was defined as the time in months from the first dosing date to the date of first documentation of progression or death due to any cause, whichever occurs first.
PFS was calculated as (first event date [if not reached, censored date as the last known event-free date] minus first dosing date plus 1) divided by 30.44.
PD: >= 20% increase in the sum of the longest dimensions of the target lesions taking as a reference the smallest sum of the longest dimensions recorded since the start of treatment, or the appearance of 1 or more new lesions.
Documentation of progression was determined from objective disease assessment based on RECIST v1.0 criteria.
|
Baseline until progression or initiation of new anti-cancer therapy or death, assessed at baseline, at the end of Cycle 1, Cycle 2, and then every other cycle.
|
|
Best Overall Response (BOR)
Tidsramme: Baseline until progression or initiation of new anti-cancer therapy or death, assessed at baseline, at the end of Cycle 1, Cycle 2, and then every other cycle.
|
BOR: best response recorded from treatment start until disease progression/recurrence based on RECIST v1.0.
Complete Response (CR): disappearance of all lesions.
Partial Response (PR): >=30% decrease in sum of longest diameters of target lesions taking as reference baseline sum of longest diameters, associated to non-progressive disease response for non target lesions.
PD: >=20% increase in sum of longest diameters of target lesions taking as reference smallest sum of longest diameters since treatment start, or appearance of >=1 new lesion, or unequivocal progression in non-target lesions.
Stable disease (SD): neither shrinkage for CR/PR nor increase for PD taking as reference smallest sum of longest diameters since treatment start.
CR and PR had to be confirmed on a follow up imaging assessment >=4 weeks after the initial objective documentation of the response.
SD must have met the SD criteria at least once after start of treatment in a minimum interval of 6 weeks.
|
Baseline until progression or initiation of new anti-cancer therapy or death, assessed at baseline, at the end of Cycle 1, Cycle 2, and then every other cycle.
|
|
Duration of Response (DR)
Tidsramme: Baseline until progression or initiation of new anti-cancer therapy or death, assessed at baseline, at the end of Cycle 1, Cycle 2, and then every other cycle.
|
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause, whichever occurs first.
Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause [if not reached, censored date] minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44.
DR was calculated for a subgroup of participants with a confirmed objective tumor response.
|
Baseline until progression or initiation of new anti-cancer therapy or death, assessed at baseline, at the end of Cycle 1, Cycle 2, and then every other cycle.
|
|
Overall Survival (OS)
Tidsramme: Randomization until death or last date known to be alive.
|
Time in months from the start of study treatment to date of death due to any cause.
OS was calculated as (the death date or last alive date minus the date of first dose of study medication plus 1) divided by 30.44.
Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).
|
Randomization until death or last date known to be alive.
|
|
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Tidsramme: Baseline (Cycle [C]1 Day 1), up to C75
|
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status (GHS), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties).
Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent').
For GHS, functional scales, symptom scales and single items, scores were averaged, transformed to 0-100 scale; higher score=better level of functioning/health or greater degree of symptoms.
Improvement was defined as a mean increase from baseline of ≥10 for GHS and functional scales or a mean decrease from baseline of ≤10 for symptom scales.
Worsened was defined as a mean decrease from baseline of ≤10 for GHS and functional scales or a mean increase from baseline of ≥10 for symptom scales.
Stable was a mean change from baseline of <10.
|
Baseline (Cycle [C]1 Day 1), up to C75
|
|
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13) Score
Tidsramme: Baseline (C1D1) up to C75
|
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week.
The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain ).
Response range: (1) not at all to (4) very much.
Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms.
Results are reported for coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, and other pain.
Improvement was defined as a mean decrease from baseline of ≤10.
Worsened was defined as a mean increase from baseline of ≥10.
Stable was a mean change from baseline of <10.
|
Baseline (C1D1) up to C75
|
|
Trough Plasma Concentrations (Ctrough) of Dacomitinib
Tidsramme: Predose on C1D14, C2D1, C3D1, C4D1
|
Results for Ctrough were summarized as per the dose received during given cycle: no dose (treatment interruption at any cycle due to treatment-related toxicity), dacomitinib 15 mg (dacomitinib 15 mg at any cycle due to treatment-related toxicity at higher doses), 30 mg (dacomitinib 30 mg at any cycle as starting dose or dose reduction due to treatment-related toxicity at higher doses), 45 mg (dacomitinib 45 mg at any cycle as starting dose or dose escalation due to satisfactory toleration of dacomitinib 30 mg treatment).
|
Predose on C1D14, C2D1, C3D1, C4D1
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O'Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, Janne PA. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015 Jul;26(7):1421-7. doi: 10.1093/annonc/mdv186. Epub 2015 Apr 21.
- Janne PA, Ou SI, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Dec;15(13):1433-1441. doi: 10.1016/S1470-2045(14)70461-9. Epub 2014 Nov 5.
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- A7471017
- 2011-002794-39 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .